Ratings Guobang Pharma Ltd.

Equities

605507

CNE100004NS2

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
18.49 ^CNY	-0.64%		+1.15%	+5.30%

Apr. 15	Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 27	Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company is highly valued given the cash flows generated by its activity.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GUOBANG PHARMA LTD.	+5.30%	1.43B	-
ELI LILLY AND COMPANY	+37.78%	705B	C+
NOVO NORDISK A/S	+32.82%	583B	B
JOHNSON & JOHNSON	-3.51%	364B	C+
MERCK & CO., INC.	+19.94%	332B	B-
ABBVIE INC.	+5.14%	291B	C+
ASTRAZENECA PLC	+16.64%	238B	B+
ROCHE HOLDING AG	-4.13%	210B	A+
NOVARTIS AG	+10.63%	209B	B-
AMGEN INC.	+9.32%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes